Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 1
2015 1
2016 1
2017 1
2018 1
2019 2
2020 2
2021 3
2022 1
2023 2
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial.
Tessoulin B, Chiron D, Thieblemont C, Oberic L, Bouadballah K, Gyan E, Damaj G, Ribrag V, Gressin R, Feugier P, Casasnovas O, Zerazhi H, Lemonnier F, Maisonneuve H, Joubert C, Van Den Neste E, Lamy T, Tilly H, Moreau A, Hermine O, Le Gouill S. Tessoulin B, et al. Bone Marrow Transplant. 2021 Jul;56(7):1700-1709. doi: 10.1038/s41409-020-01198-2. Epub 2021 Mar 3. Bone Marrow Transplant. 2021. PMID: 33658645 Free article. Clinical Trial.
The platinum derivative (PD) choice was free: R-DHA-cisplatin, R-DHA-carboplatin, or R-DHA-oxaliplatin. We investigated the prognostic impact of each PD. ...The 4-year OS was 92% for R-DHAOx versus 75.9% for R-DHACis/DHACa (HR = 0.37, p = 0.03). …
The platinum derivative (PD) choice was free: R-DHA-cisplatin, R-DHA-carboplatin, or R-DHA-oxaliplatin. We investigated …
Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer.
Fanti S, Goffin K, Hadaschik BA, Herrmann K, Maurer T, MacLennan S, Oprea-Lager DE, Oyen WJ, Rouvière O, Mottet N, Bjartell A. Fanti S, et al. Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):469-476. doi: 10.1007/s00259-020-04934-4. Epub 2020 Jul 2. Eur J Nucl Med Mol Imaging. 2021. PMID: 32617640 Free PMC article.
A worldwide survey on incidence, management, and prognosis of oesophageal fistula formation following atrial fibrillation catheter ablation: the POTTER-AF study.
Tilz RR, Schmidt V, Pürerfellner H, Maury P, Chun KRJU, Martinek M, Sohns C, Schmidt B, Mandel F, Gandjbakhch E, Laredo M, Gunawardene MA, Willems S, Beiert T, Borlich M, Iden L, Füting A, Spittler R, Gaspar T, Richter S, Schade A, Kuniss M, Neumann T, Francke A, Wunderlich C, Shin DI, Meininghaus DG, Foresti M, Bonsels M, Reek D, Wiegand U, Bauer A, Metzner A, Eckardt L, Popescu SȘ, Krahnefeld O, Sticherling C, Kühne M, Nguyen DQ, Roten L, Saguner AM, Linz D, van der Voort P, Mulder BA, Vijgen J, Almorad A, Guenancia C, Fauchier L, Boveda S, Greef Y, Da Costa A, Jais P, Derval N, Milhem A, Jesel L, Garcia R, Poty H, Khoueiry Z, Seitz J, Laborderie J, Mechulan A, Brigadeau F, Zhao A, Saludas Y, Piot O, Ahluwalia N, Martin C, Chen J, Antolic B, Leventopoulos G, Özcan EE, Yorgun H, Cay S, Yalin K, Botros MS, Mahmoud AT, Jędrzejczyk-Patej E, Inaba O, Okumura K, Ejima K, Khakpour H, Boyle N, Catanzaro JN, Reddy V, Mohanty S, Natale A, Blessberger H, Yang B, Stevens I, Sommer P, Veltmann C, Steven D, Vogler J, Kuck KH, Merino JL, Keelani A, Heeger CH. Tilz RR, et al. Eur Heart J. 2023 Jul 14;44(27):2458-2469. doi: 10.1093/eurheartj/ehad250. Eur Heart J. 2023. PMID: 37062040 Free PMC article.
Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study.
Costes-Tertrais D, Hueso T, Gastinne T, Thieblemont C, Oberic L, Bouabdallah K, Garciaz S, Tchernonog E, Dartigeas C, Ribrag V, Fogarty P, Casasnovas RO, Houot R, Delette C, Malak S, Fornecker LM, Gressin R, Damaj G, Le Gouill S. Costes-Tertrais D, et al. Bone Marrow Transplant. 2022 Apr;57(4):627-632. doi: 10.1038/s41409-022-01596-8. Epub 2022 Feb 11. Bone Marrow Transplant. 2022. PMID: 35149851
We performed a cross-study analysis to better evaluate BeEAM. Thirty-five patients from a retrospective study who received R-DHAP/BeEAM were compared to 245 patients from the LyMa trial (NCT00921414) who all received R-DHAP followed by R-BEAM. ...PFS and OS a …
We performed a cross-study analysis to better evaluate BeEAM. Thirty-five patients from a retrospective study who received R-DHAP/BeE …
Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921.
Brivio E, Pennesi E, Willemse ME, Huitema ADR, Jiang Y, van Tinteren HDR, van der Velden VHJ, Beverloo BH, den Boer ML, Rammeloo LAJ, Hudson C, Heerema N, Kowalski K, Zhao H, Kuttschreuter L, Bautista Sirvent FJ, Bukowinski A, Rizzari C, Pollard J, Murillo-Sanjuán L, Kutny M, Zarnegar-Lumley S, Redell M, Cooper S, Bertrand Y, Petit A, Krystal J, Metzler M, Lancaster D, Bourquin JP, Motwani J, van der Sluis IM, Locatelli F, Roth ME, Hijiya N, Zwaan CM. Brivio E, et al. J Clin Oncol. 2024 Mar 1;42(7):821-831. doi: 10.1200/JCO.23.00897. Epub 2023 Nov 30. J Clin Oncol. 2024. PMID: 38033284 Free PMC article. Clinical Trial.
The primary objective of this first-in-child trial was to determine the recommended phase II dose (RP2D) for pediatric R/I and ND patients. PATIENTS AND METHODS: In the phase I part of this international, open-label trial (ClinicalTrials.gov identifier: NCT04258943), child …
The primary objective of this first-in-child trial was to determine the recommended phase II dose (RP2D) for pediatric R/I and ND pat …
INSPEX: Optimize Range Sensors for Environment Perception as a Portable System.
Foucault J, Lesecq S, Dudnik G, Correvon M, O'Keeffe R, Di Palma V, Passoni M, Quaglia F, Ouvry L, Buckley S, Herveg J, di Matteo A, Rakotovao T, Debicki O, Mareau N, Barrett J, Rea S, McGibney A, Birot F, de Chaumont H, Banach R, Razavi J, Ó'Murchú C. Foucault J, et al. Sensors (Basel). 2019 Oct 8;19(19):4350. doi: 10.3390/s19194350. Sensors (Basel). 2019. PMID: 31597341 Free PMC article.
Safety and efficacy of temsirolimus in combination with three different immuno-chemotherapy regimens in relapse and refractory mantle cell lymphoma, final results of the T3 phase IB trial of the LYSA.
Tessoulin B, Bouabdallah K, Burroni B, Lamy T, Gressin R, Cartron G, Thieblemont C, Sarkozy C, Haioun C, Casasnovas O, Joubert C, Gyan E, Hermine O, Le Gouill S. Tessoulin B, et al. Ann Hematol. 2020 Aug;99(8):1771-1778. doi: 10.1007/s00277-020-04159-3. Epub 2020 Jun 29. Ann Hematol. 2020. PMID: 32601796 Clinical Trial.
In the T(3) phase Ib clinical trial, we investigated the recommended dose of temsirolimus in association with R-CHOP (R-CHOP-T), or high-dose cytarabine plus rituximab (R-DHA-T), or fludarabine, cyclophosphamide plus rituximab (R-FC-T). ...Determinatio …
In the T(3) phase Ib clinical trial, we investigated the recommended dose of temsirolimus in association with R-CHOP (R-CHOP-T …
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.
Sharman JP, Coutre SE, Furman RR, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn IW, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Tausch E, Cramer P, Huang J, Mitra S, Hallek M, O'Brien SM, Stilgenbauer S. Sharman JP, et al. J Clin Oncol. 2019 Jun 1;37(16):1391-1402. doi: 10.1200/JCO.18.01460. Epub 2019 Apr 17. J Clin Oncol. 2019. PMID: 30995176 Free PMC article. Clinical Trial.
PATIENTS AND METHODS: Patients were randomly assigned to receive rituximab in combination with either IDELA 150 mg twice daily (IDELA/R; n = 110) or placebo (placebo/R; n = 110). Key end points were progression-free survival (PFS), overall response rate (ORR), overa …
PATIENTS AND METHODS: Patients were randomly assigned to receive rituximab in combination with either IDELA 150 mg twice daily (IDELA/R …
Global structural integrity and effective connectivity in patients with disorders of consciousness.
Bodart O, Amico E, Gómez F, Casali AG, Wannez S, Heine L, Thibaut A, Annen J, Boly M, Casarotto S, Rosanova M, Massimini M, Laureys S, Gosseries O. Bodart O, et al. Brain Stimul. 2018 Mar-Apr;11(2):358-365. doi: 10.1016/j.brs.2017.11.006. Epub 2017 Nov 11. Brain Stimul. 2018. PMID: 29162503 Free article.
No other predictors (age, gender, time since onset, behavioural score) improved the models. FA and PCI were correlated in the whole population (r = 0.86, p < 0.0001), the patients, and the healthy subjects subgroups. ...
No other predictors (age, gender, time since onset, behavioural score) improved the models. FA and PCI were correlated in the whole populati …
Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
Italiano A, Miller WH Jr, Blay JY, Gietema JA, Bang YJ, Mileshkin LR, Hirte HW, Higgins B, Blotner S, Nichols GL, Chen LC, Petry C, Yang QJ, Schmitt C, Jamois C, Siu LL. Italiano A, et al. Invest New Drugs. 2021 Dec;39(6):1587-1597. doi: 10.1007/s10637-021-01141-2. Epub 2021 Jun 28. Invest New Drugs. 2021. PMID: 34180037 Free PMC article. Clinical Trial.
13 results